Jaguar Health to Implement 1-for-25 Reverse Stock Split

Published on 18/03/2025 at 18:33 - Modified on 18/03/2025 at 18:35

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Jaguar Health, Inc.

Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	25/06	MT
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	11/06	MT
Jaguar Health Prices Offering of Shares, Warrants	21/05	MT
Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025	19/05
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Jaguar Health, Inc. - Special Call	30/04
Jaguar Health, Inc. and Napo Therapeutics Announce Initial Proof-Of-Concept Results	30/04	CI
Jaguar Health, Inc., Q4 2024 Earnings Call, Mar 31, 2025	31/03
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	31/03	CI
Jaguar Health, Inc. announced that it has received $3.4 million in funding	31/03	CI
Jaguar Health, Inc. Auditor Raises 'Going Concern' Doubt	31/03	CI
Sector Update: Health Care Stocks Lower Late Afternoon	27/03	MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	26/03	MT
Sector Update: Health Care	26/03	MT
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall	26/03	MT
Jaguar Health, Inc. announced that it expects to receive $3.4 million in funding	26/03	CI
Jaguar Health to Implement 1-for-25 Reverse Stock Split	18/03	MT
Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Enter into an Amendment with Streeterville Capital, LLC	21/02	CI
Jaguar Health, Inc., Q3 2024 Earnings Call, Nov 13, 2024	13/11
Earnings Flash (JAGX) JAGUAR HEALTH Posts Q3 Revenue $3.1M	13/11	MT
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs	06/11	CI
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024	24/24/24	CI
Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment	27/24/27	MT
Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods	19/24/19	MT